Women's Health

---

Our first indication is Bacterial Vaginosis (BV), a type of inflammation that results in recurrent infections,  disruption of homeostasis and longer-term complications in women of reproductive ages.

It impacts almost a third of all women.  

BV is marked by an alteration in the balance of the "good" vs. the "bad" bacteria (dysbiosis) in the vagina, i.e.  the lactobacilli, which are inhabitants of the healthy vaginal microbiome get outnumbered by polymicrobial biofilms of pathogenic bacteria. This overgrowth results in a fishy odor, higher vaginal pH ( >4.5) and vaginal epithelial barrier dysfunction.

Some of the secondary effects of BV include urinary tract and yeast infections, miscarriages and preterm births, fertility  issues, pelvic inflammatory disease and increased rates of STDs. 

The current standard of care for BV are antibiotics that do not prevent recurrence, are non-selective in some cases and not active against drug-resistant pathogens. 

Therefore, we are leading efforts to address BV via topical therapeutics that can rapidly eliminate pathogenic bacteria while leaving the beneficial or commensal bacteria  intact.